Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Filgotinib in Rheumatoid Arthritis
2024-513919-27-00Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in rheumatoid arthritis (RA), sponsored by Alfasigma. Primary endpoint: Safety. Started Jul 2024; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-513919-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513919-27-00.